NDAORALCAPSULE
Approved
Sep 1964
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 5h ago · AI intelligence enriched 6d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ALBAMYCIN (novobiocin sodium) is an oral antibiotic capsule approved by Pfizer in 1964 for bacterial infections. It is a small-molecule antibiotic that inhibits bacterial DNA gyrase, making it effective against Gram-positive and some Gram-negative bacteria. The drug is now approaching loss of exclusivity with significant generic competition in the market.
LOE Approaching
With LOE approaching and moderate competitive pressure (30%), commercial teams are likely in transition mode with smaller field forces managing decline.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on ALBAMYCIN offers limited career advancement opportunity given its LOE-approaching status and minimal linked job openings (0 identified). This assignment is best suited for professionals managing portfolio decline, cost optimization, or seeking experience in legacy product stewardship rather than growth-oriented innovation.
Brand Manager (Legacy Products)Sales Representative (Generic Transition)
Worked on ALBAMYCIN at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.